The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; ...

Giselle Mosnaim, MD, an allergist and immunologist at Endeavor Health, discusses Rhapsido® (remibrutinib), a new FDA-approved oral therapy for chronic ...

The risk for MASLD was significantly reduced by 14.7 and 13.5%, respectively, by replacing 330g/day of sugar-sweetened beverages or low- or non-sugar-sweetened beverages with water.

The approval was based on the C-POST study which evaluated cemiplimab in adults with CSCC at high risk of recurrence after surgery and radiation.

The Food and Drug Administration (FDA) has expanded the approval of Simponi ® (golimumab) to include pediatric patients weighing at least 15kg with moderate to severely active ulcerative colitis (UC).

The investigational agent is expected to provide protection against all known strains of seasonal influenza with a single dose.

Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF.

The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.

Positivity decreased for 2vHPV, 4vHPV, and 9vHPV for vaccinated and unvaccinated participants from 2006 to 2023.

The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.

Heightened risk seen for many conditions, including myocarditis, blood clots, kidney damage, abnormal heart rhythms, headache, and fatigue.